Ipilimumab Adjuvant Therapy in Melanoma

被引：6

作者：

Copur, Mehmet S. ^{[1
]}

Ramaekers, Ryan ^{[1
]}

Crockett, David ^{[1
]}

机构：

[1] CHI Hlth St Francis Canc Treatment Ctr, Grand Isl, NE 68803 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 04期

关键词：

D O I：

10.1056/NEJMc1615564

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：398 / 399

页数：2

共 4 条

[1]

Copur MS, 2011, NEW ENGL J MED, V365, P1257, DOI 10.1056/NEJMc1108661

[2]

Robert C, 2011, NEW ENGL J MED, V365, P1257

[3]

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma [J].

Schadendorf, Dirk ;

Hodi, F. Stephen ;

Robert, Caroline ;

Weber, Jeffrey S. ;

Margolin, Kim ;

Hamid, Omid ;

Patt, Debra ;

Chen, Tai-Tsang ;

Berman, David M. ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1889-U48

[4]

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study [J].

Wolchok, Jedd D. ;

Neyns, Bart ;

Linette, Gerald ;

Negrier, Sylvie ;

Lutzky, Jose ;

Thomas, Luc ;

Waterfield, William ;

Schadendorf, Dirk ;

Smylie, Michael ;

Guthrie, Troy, Jr. ;

Grob, Jean-Jacques ;

Chesney, Jason ;

Chin, Kevin ;

Chen, Kun ;

Hoos, Axel ;

O'Day, Steven J. ;

Lebbe, Celeste .

LANCET ONCOLOGY, 2010, 11 (02) :155-164

← 1 →